AstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a treatment of patients with a form of non-small cell lung cancer.
TOKYO -- Japan's Ryohin Keikaku, owner of the Muji retail brand, will open small stores specializing in inexpensive items in China, starting this summer, its first such outlets located overseas ...
BEIJING, Jan 27 (Reuters) - China on Monday issued guidelines on strengthening supervision of trust companies, aiming to bolster risk control within the trust industry, according to a statement ...
Taipan, a small village in SW China’s Guizhou, has become a national and international sensation for its village basketball games. Ahead of the #SpringFestival2025, it held another major ...
HONG KONG, Jan 28 (Reuters) - China is aiming to beef up physical education in schools, making it core to the curriculum rather than a secondary subject, authorities said as they push for a more ...
Lung cancer combination advances in China In other news today ... AstraZeneca's EGFR inhibitor Tagrisso (osimertinib) in non-small cell lung cancer (NSCLC) patients with MET amplification after ...